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OBJECTIVEdTo assess the validity of self-report measures of diabetes medication adherence
and evaluate the effect of depression on the validity of these reports.
RESEARCH DESIGN AND METHODSdAdults with type 2 diabetes, treated with oral
medications, completed a set of medication adherence self-reports that varied response scales
and time frames, were administered structured clinical interviews for depression, and provided
blood samples for HbA1c as part of a screening for an intervention study. A subsample of par-
ticipants with HbA1c $7.0% and clinically signiﬁcant depression received Medication Event
Monitoring System (MEMS) bottle caps to record adherence. Analyses examined relationships
between adherence measures and HbA1c and, in the subsample, MEMS. Moderated linear re-
gression evaluated whether depression severity modiﬁed relationships with HbA1c.
RESULTSdParticipant (n = 170, 57% men, 81% white, mean HbA1c 8.3% [SD, 1.7]) adher-
enceself-reportsweresigniﬁcantly(r=20.18to 20.28;P,0.03)associatedwith lowerHbA1c.
In the subsample (n = 88), all self-reports were signiﬁcantly (r =0 . 3 5t o0 . 5 5 ;P # 0.001)
associated with MEMS-measured adherence. Depression signiﬁcantly moderated the relation-
ship between three of six self-reports and HbA1c; at high levels of depression, associations with
HbA1c became nonsigniﬁcant.
CONCLUSIONSdResultssupportthevalidityofeasilyadministeredself-reportsfordiabetes
medication adherence. One-month, percentage-based ratings of adherence had the strongest
associations with MEMS and HbA1c; those requiring the report of missed doses had weaker
associations.One-weekself-ratingsand measuresthatrequirerespondentstorecordthenumber
of missed doses appear to be vulnerable to bias from depression severity.
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T
reatment nonadherence is a com-
mon and important problem in di-
abetes care that negatively impacts
treatment outcomes (1). Many studies
have focused on the identiﬁcation of fac-
tors that contribute to adherence and on
theevaluationofinterventionstoimprove
adherence. However, the value of these
studies is often limited by measurement
challenges in the assessment of medica-
tion adherence. Although objective mea-
sures, such as electronic monitoring caps
that record the timing of pill bottle open-
ings, are often thought to be preferable to
subjective self-reports, they are costly, of-
ten not feasible for certain study designs,
and are impractical for clinical practice.
Given thecontinuedneedforvalidadher-
ence self-report measures, understanding
the factors that inﬂuence the validity of
self-reports remains important (2). How-
ever, information on the validity of self-
reported medication adherence often
goes unreported in studies investigating
the psychometric properties of widely
used diabetes treatment adherence scales
(3), and few studies focus directly on the
issue of validity in the evaluation of self-
reported medication adherence mea-
sures.
For self-report measures of diabetes
medication adherence to be valid, there
should be evidence of a robust correlation
with other adherence measures, preferably
those not subject to the biases associ-
ated with self-report (concurrent validity).
In addition, because diabetes medication
adherence has a causal impact on glycemic
control, participants’ adherence self-reports
should correlate with HbA1c levels (crite-
rion validity). Relationships with HbA1c
levelsareexpectedtoberelativelyweaker
than with other measures of adherence
because medication adherence is not
the only factor that impacts glycemic
control (2).
Nevertheless, studies often rely exclu-
sivelyonHbA1ctodemonstratethevalidity
of adherence measures in diabetes. For ex-
ample, studies have documented signiﬁ-
cant relationships between self-reported
adherence and HbA1c in adults with type
2 diabetes, using versions of the Morisky
Medication Adherence Scale (4–8) and
other self-reports of medication adherence
(9,10). Other large studies, however, have
failed to ﬁnd relationships between simi-
larly measured self-reported adherence
and HbA1c (11). Relatively few studies
have examined the relationship between
self-reported adherence and objectively
monitored medication adherence; fewer
still have examined how the characteristics
of self-report questions affect this relation-
ship.
Signiﬁcantly closer concordance has
beenobservedbetweensingle-itemglobal
self-ratings of adherence and concur-
rently assessed adherence measured by
electronic monitoring cap, compared
with the concordance for self-report
measures that focused on frequency of
missed doses in HIV/AIDS (12). The re-
called time frame of these measures also
related to concordance: 1-month recall
periods were more accurate than 3- and
7-day recall periods (12). Another study
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ORIGINAL ARTICLEfound that electronically-monitored ad-
herence to cholesterol-lowering medica-
tion and a modiﬁed version of the
Morisky scale were each associated with
cholesterol lowering, whereas other ad-
herence methodsdsuch as pill counts,
the original Morisky scale, and recall
questions about missed dosesddid not
predict cholesterol lowering (13). These
studiesarerareintheirexaminationofthe
inﬂuence of measurement characteristics
on the validity of medication adherence
self-reports.
The current study sought to evaluate
thevalidity offourself-reportmeasuresof
medicationadherenceinasampleofadult
patients with type 2 diabetes treated with
oral medications for diabetes and related
conditions (i.e., hypercholesterolemia,
hypertension) who were recruited for a
depression treatment trial. Because de-
pression has been consistently associated
with treatment nonadherence in diabetes,
including self-reported and objectively
monitored adherence (14), and in light
of the literature linking mood and biases
in memory and recall (15–17), we also
used a detailed assessment of depression
to evaluate whether depression severity
inﬂuenced the validity of self-reports for
medication adherence.
RESEARCH DESIGN AND
METHODS
Study samples and procedures
Participants were recruited from the Di-
abetes Center and primary care clinics at
Massachusetts General Hospital or were
self-referred via hospital e-mail mailing
lists and radio advertisements for a larger
intervention study on the efﬁcacy of cog-
nitive behavioral therapy for adherence
and depression (18) in patients with
type 2 diabetes. Entry criteria for the
study included the ability to read and
write in English, a diagnosis of type 2
diabetes, a prescription for medication
to treat hyperglycemia (either insulin or
oral medication) and taking oral medica-
tionfordiabetesoradiabetes-relatedcon-
dition (i.e., hypercholesterolemia or
hypertension), and age between 18 and
70 years. Analyses indicated no signiﬁ-
cant differences in the relationships of
self-reported adherence to HbA1c levels
for patients not taking an oral antihyper-
glycemic medication (because they were
taking insulin only; n = 25) versus those
who were taking an oral antihyperglyce-
mic medication, so both groups of partic-
ipants were included.
To qualify for the intervention study
and to receive an electronic bottle cap,
participants were required to meet DSM-
IV criteria for major depressive disorder
(MDD)ordysthymiaortoexhibitclinically
signiﬁcant depressive symptoms despite
the prescription of an antidepressant.
They were also required to have an HbA1c
$7.0%. Prescriptions for diabetes and
depression medications were required
to have been stable for 2 months. Those
with severe mental illness requiring im-
mediate treatment or precluding ability
toparticipatewereexcluded.Participants
providedinformedconsent,andthePart-
ners HealthCare Institutional Review
Board approved the study.
All participants were evaluated for
depression severity, completed all self-
report measures, and provided a blood
sampleto measure HbA1clevelsat the ini-
tial baseline evaluation. Self-report ques-
tions for medication adherence asked
participants about their adherence to
their overall diabetes-related oral medi-
cation regimen (i.e., prescribed for hy-
perglycemia, hypercholesterolemia, or
hypertension). The subsample of partic-
ipantswhoqualiﬁedfortheintervention
were given an electronic pill bottle cap
at the baseline visit and were asked to
continue using it until their next study
visit. Thus, the electronically monitored
adherence assessment followed the self-
reportsandcapturedonlypre-intervention
data.
Measures
Depression severity. The Montgomery
Åsberg Depression Rating Scale (19), a
structured clinical assessment of 10 com-
monly occurring symptoms of depres-
sion over the past week, was used to
measure depression symptom severity.
Scores range from 0 to 60: 0–6 indicates
no depression; 7–19 indicates mild de-
pression; 20–34 indicates moderate de-
pression; and 35–60 indicates severe
depression. Internal reliability was high
(a =0 . 8 5 ) .
Self-ratings for medication adherence.
Questions developed by Lu et al. (12) to
assess adherence to antiretroviral medica-
tions over the past month were adapted to
assessadherencetooraldiabetes-relatedmed-
ications. The instructions for all self-ratings
were as follows: “The following questions
ask about your diabetes medications. This
includes oral medications you take for di-
abetes,highbloodpressure,andhighcho-
lesterol.” Participants were asked to
quantitatively evaluate their adherence
using 11 response categories (0, 10,
20...100%) with the question, “What
percent of the time did you take all your
diabetes medications as your doctor
prescribed?” Participants were also
asked to qualitatively rate their adher-
ence (rating scale: very poor, poor,
fair, good, very good, excellent) with,
“On average, how would you rate your
ability to take all your diabetes medica-
t i o n sa sy o u rd o c t o rp r e s c r i b e d ? ” As in
Luetal.(12), participants wereaskedto
respond considering the past month.
One-week time frames were added to fa-
cilitate comparison with other measures.
Other adherence self-reports. On the
basis of the approach of the AIDS Clinical
Trials Group (ACTG) Adherence Ques-
tionnaire (20), we asked participants to
report the number of prescribed doses
for each diabetes-related medication and
record the number of missed doses, per
medication, during the past 7 days. We
refer to this measure as “missed doses.”
A calendar was used to facilitate recall,
and adherence was calculated as the per-
centage of prescribed doses taken for the
past week. For participants taking multi-
ple medications, a mean percentage of
doses taken across medications was cal-
culated. Participants also completed an
item from the Summary of Diabetes Self
CareActivities(SDSCA),whichaskedpar-
ticipants, “On how many of the last seven
days did you take your recommended di-
abetes medication” (21). We refer to this
measure as “adherent days.”
Electronically monitored medication
adherence. Medication Event Monitor-
ing System (MEMS)bottlecapswere used
to track one medication per participant.
For participants taking an antihypergly-
cemic medication, MEMS caps tracked
the antihyperglycemic medication that
the participant took the most frequently
or found most difﬁcult to remember. For
the 25 participants taking insulin and no
oral antihyperglycemic medication,
hypertension- or hypercholesterolemia-
related medications were monitored.
MEMS adherence was calculated to pro-
vide the percentage of doses taken by
dividing the number of times a bottle was
opened by the number of openings pre-
scribed during the time frame. Trained
assessors followed the approach used by
Safren et al. (22) to correct MEMS data
only if participants could identify a day
on the calendar when they took their
medication in a way that it would not be
recorded by MEMS (e.g., took out two
pills in the morning and pocketed one
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Validity of self-reported adherencefor later that day). Participants were re-
quired to have at least 5 days of MEMS
data for the current analyses.
Other measures. Participants com-
pleted a structured interview of psychiat-
ric diagnoses (23) and provided a blood
sample for HbA1c at the baseline visit,
whichwasanalyzedatthesamehospital
laboratory. They also completed study-
generatedquestionnairesregardingtheir
treatment regimen, comorbid illnesses,
presence of diabetes complications, time
since diagnosis, and demographic and so-
cioeconomic factors.
Data analysis
A l la n a l y s e sw e r ed o n ei nS P S S1 8 . 0
software. All variables were examined
for normality and were analyzed as con-
tinuous. The missed doses measure was
not normally distributed; therefore, cor-
relations and regression analyses for this
variable are based on a base 10 logarithm
of the original data. Bivariate correlations
were used to determine correlations be-
tween HbA1c, MEMs data, and self-report
adherence data. We used Williams’ t test
(Wt) (24) to compare the strength of cor-
relations across adherence measures.
Computations based on those of Lu
et al. (12), transformed the 6-point Likert
scalesofthequalitativeself-ratingitemsto
100-point scales (0, 20, 40, 60, 80, and
100). We then calculated means and SDs
for all indices of adherence on a 0–100
scale and computed discrepancies be-
tween self-reported adherence and
MEMS adherence.
Multivariate linear regression anal-
yses focused on HbA1c (rather than
MEMS) because it was available for the
full sample. Sex, age, education, and the
prescription of insulin were evaluated as
potential covariates to be included in
multivariate analyses if signiﬁcantly cor-
relatedwithHbA1corMEMS.Becausede-
pression was a focus of the study, we
evaluated evidence for whether depres-
sion severity moderated the relationship
between self-reported adherence and
HbA1c through interaction terms, with
appropriate post hoc probing of signiﬁ-
cant moderation effects. This procedure
involved the computation of two condi-
tional variables for depression, one in
which lower depression severity was
coded as 1 SD below the centered mean
and one in which higher depression se-
verity was coded as 1 SD above. The
slopes of these analyses were then used
to plot regression lines for the relation-
ship between self-reports and HbA1c at
high and low levels of depression severity
(25). We did not examine MEMS in these
moderation analyses because of the
smaller subsample with available data.
Thissubsamplealsohadarestrictedrange
of depression severity and glycemic con-
trol as a result of our design.
RESULTSdWe limited our analyses to
the 170 screened participants who
provided a baseline HbA1c and answered
the self-reported adherence questions. Of
these, 88 qualiﬁed for the intervention
study and provided MEMS cap data before
intervention. The average number of days
of adherence collected by MEMS caps was
20.59 (SD, 11.81). Number of days of
monitoring was not signiﬁcantlyassociated
with MEMS adherence (P . 0.10).
Sociodemographic and background
characteristics
Ofthe170participantsincludedintheﬁrst
setofanalyses,56.5%weremen,81%were
white, mean age was 56 years (SD,10) and
mean HbA1c was 8.3% (SD, 1.7). Partici-
pants had an average of 14 years (SD, 3) of
education, and 59% qualiﬁed for a diagno-
sis of MDD. Of the 88 people given an
MEMS cap, 52.3% were men and their
mean age was 57 years (SD, 8). These
participants had an average of 14 years
(SD, 3) of education, 84% were white,
mean HbA1c was 8.8% (SD, 1.6), and
74%metcriteriaforMDD.Table1presents
descriptive statistics for those inthe overall
sample and for the subsample included in
the MEMS analyses. Consistent with the
expected effects of the intervention’ss e l e c -
tioncriteria,MEMSparticipantshadsignif-
icantly more severe Montgomery Åsberg
Depression Rating Scale scores (t [166] =
–3.77, P , 0.001) and were more likely to
meet diagnostic criteria for MDD (x
2 [1,
n = 168] = 21.87, P , 0.001) than those
who did not qualify for the intervention.
They also had a signiﬁcantly longer du-
ration of diabetes (t [164] = 22.71, P =
0.008) and were more likely to be on
insulin (x
2 [1, n = 168] = 8.81, P =0 . 0 0 3 ) .
Correlations between adherence and
HbA1c
All adherence self-report items were signif-
icantlyandinverselycorrelatedwithHbA1c.
MEMSadherenceandHbA1cweresimilarly
signiﬁcantly correlated (r = 20.25, P =
0.021; see ﬁrst two data columns in
Table2).Comparingcorrelationcoefﬁcients
revealed no signiﬁcant differences in corre-
lations between any of the self-report mea-
sures and HbA1c levels (all P . 0.17).
Table 1dParticipant characteristics
Total sample MEMS participants
n =1 7 0 n =8 8
Age (years) 55.59 (9.59) 56.64 (8.23)
Education (years) 14.48 (3.23) 14.44 (3.21)
Years since diagnosis 12.70 (8.50) 14.43 (8.61)
HbA1c 8.28 (1.65) 8.83 (1.63)
Male sex 57 53
White race 81 84
Unemployed 12 14
On disability 19 19
On insulin 48 60
MADRS total 22.25 (10.23) 24.88 (8.28)
Diagnosed with MDD 59 74
Missed doses (week) 10.96 (16.60)
a 12.08 (17.79)
a
Adherent days (week) 6.05 (1.60)
b 5.98 (1.59)
b
Qualitative self-rating
Week 4.59 (1.40)
c 4.57 (1.38)
c
Month 4.39 (1.50)
c 4.32 (1.55)
c
Quantitative self-rating
Week 81.41 (23.11)
d 82.27 (22.48)
d
Month 80.47 (23.40)
d 78.30 (25.15)
d
MEMS N/A 78.92 (25.23)
d
Data are mean (SD) or percentage. MADRS, Montgomery Åsberg Depression Rating Scale. N/A, not appli-
cable.
aPercentage of doses missed.
bNumber of days when diabetes medications were taken as prescribed.
c1=v e r yp o o r ,2=p o o r ,3=f a i r ,4=g o o d ,5=v e r yg o o d ,6=e x c e l l e n t .
dPercentage of adherence.
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Gonzalez and AssociatesCorrelations between self-reported
and MEMS adherence
All correlations between self-reported ad-
herence and MEMS were positive and
signiﬁcant (see third and fourth data
columns in Table 2). Comparisons by
Wt test indicated that the quantitative
1-week adherence self-rating was more
strongly correlated to MEMS adherence
than the qualitative 1-week self-rating
(Wt = 20.29, P = 0.005) and missed
doses during the past week (Wt =
23.49, P , 0.001). In addition, the
1-month quantitative adherence self-
rating was more strongly correlated to
MEMS than the 1-month qualitative self-
rating(Wt=23.22,P=0.002).Therewas
no difference between the 1-week quan-
titative self-rating and the 1-month quan-
titativeself-rating(Wt=21.02,P=0.31).
The remaining comparisons were not sig-
niﬁcant (P . 0.06).
Self-reported adherence and MEMS
discrepancies
Reported adherence, expressed as a per-
centage, was highest for missed doses of
medication and lowest for 1-month quali-
tative self-ratings (see ﬁfth data column in
Table 2). Discrepancies between self-
reported adherence and subsequent
MEMS adherence are presented in the
last column of Table 2 and show that
1-month qualitative self-ratings and
missed doses tended to have the greatest
discrepancy with MEMS data, whereas
quantitative self-ratings showed closest
concordance. Mean differences were
smallest, and near zero, for the 1-month
percentage-based rating. Age, depression
severity, and education were not signiﬁ-
cantly related to these discrepancies (data
not shown).
Multiple regression and moderation
analyses
Of potential covariates, only insulin use
was signiﬁcantly associated with HbA1c
(r = 0.32, P = 0.003) and was included
in the multivariate models. Results from
separate regression models for each mea-
sureofself-reportedadherencearepresented
in Table 3. The inclusion of depression
severity as a main effect did not meaning-
fully attenuate relationships between self-
reports and HbA1c. However, several
signiﬁcant moderation effects were found.
Speciﬁcally, depression severity was a sig-
niﬁcant moderator of the relationship
between 1-week qualitative adherence
self-ratings (P = 0.025) and 1-week quan-
titative self-ratings (P = 0.046) and HbA1c.
A signiﬁcant interaction (P , 0.001) was
also found between depression and re-
ports of missed doses. Post hoc probing
of these signiﬁcant interaction effects
showed that the relationship between
self-reported adherence and HbA1c was
negative and signiﬁc a n ta tl o wl e v e l so f
depressionseveritybutnearzeroandnon-
signiﬁcant at high levels (Fig. 1).
CONCLUSIONSdThe ﬁndings from
this study support the validity of easily
administeredself-reportmeasurestoassess
medicationadherenceinadultswithtype2
diabetes. We compared self-reported and
MEMS-measured adherence and found
signiﬁcant correlations for all self-report
items, suggesting that self-reported adher-
encesharesasigniﬁcantamount(7–30%)of
variance with objectively monitored adher-
ence, our proximal indicator of validity.
This was found despite the lack of overlap
intimeframesandeventhoughMEMSonly
monitoredonemedicationwhereastheself-
report items required participants to con-
sider their diabetes-related oral medications
in aggregate. These associations, especially
those for the percentage-based global self-
ratings, were considerably stronger than
those found by a previous study of more
than 500 patients with type 2 diabetes be-
tween the 4-item self-report Morisky Medi-
cationAdherenceScaleortheadherentdays
item from the SDSCA and pharmacy reﬁll
records (4% shared variance each) (11).
A previous study of more than 800 patients
with heart failure or hypertension also
found a weaker correlation between self-re-
ported medication adherence based on a
modiﬁed version of the Morisky scale, and
MEMS adherence (9.6% shared variance)
(26). Our results suggest that part of the
v a r i a t i o ni nt h ea m o u n to ft h es h a r e dv a r i -
ancebetweenself-reportsandMEMSadher-
ence can be attributed to measurement
characteristics (discussed in detail below).
The relatively more modest relation-
ships between adherence and HbA1c were
expected, because glycemic control is af-
fected by a variety of factors beyond med-
ication adherence, including diet and
exercise, degree of insulin deﬁciency, and
adequacy of the prescribed treatment regi-
men. Although modest relationships be-
tween adherence self-reports and HbA1c
are often interpreted as reﬂecting the lim-
ited validity of these measures, this may
not be an appropriate conclusion. For
example,arecentmeta-analysisof21stud-
ies in pediatric type 1 diabetes indicated
that adherence and glycemic control share
less than 8% of their variance. No differen-
ces in the strength of this association were
found for studies that used self-reported
adherence versus those that used objective
meter downloads (27). Similarly, in a large
sample of adults with type 2 diabetes, ob-
jective pharmacy reﬁll data were signiﬁ-
cantly associated with current HbA1c and
change in HbA1c over time; however, the
amount ofvariance explainedwas only4%
and 1.7%, respectively (28). Thus, it is
important to recognize that validating
adherence self-reports based only on rela-
tionships with clinical outcomes such as
HbA1cmayleadtolessaccurateconclusions
because of the relatively modest impact
of adherence on this outcome (2,29). The
Table 2dValidity and descriptive data for adherence measures
Correlations
a Descriptive statistics
b
Adherence measure HbA1c P MEMS P Percentage
c
MEMS
discrepancy
d
Missed doses (week) 20.203 0.011 0.270 0.012 88.92 (17.79) 9.23 (26.27)
Adherent days (week) 20.176 0.030 0.391 ,0.001 85.38 (22.66) 6.53 (26.67)
Qualitative self-rating
Week 20.211 0.006 0.345 0.001 71.36 (27.59) 27.56 (30.30)
Month 20.239 0.002 0.384 ,0.001 66.36 (31.01) 212.56 (31.57)
Quantitative self-rating
Week 20.221 0.004 0.506 ,0.001 82.27 (22.48) 3.35 (23.82)
Month 20.282 ,0.001 0.549 ,0.001 78.30 (25.15) 0.85 (23.54)
MEMS 20.246 0.021 d 78.92 (25.22) d
aData are Pearson correlation coefﬁcients with two-tailed P values.
bData are means and, in parentheses,
standard deviations.
cData are presented as percentage adherence for all measures, using reverse coding for
missed doses and conversion to percentage-based scale for adherent days and qualitative self-ratings to fa-
cilitate comparisons across measures.
dDiscrepancies were calculated by subtracting MEMS percentage of
adherence from the percentage value for each self-report measure; thus, positive values indicate a tendency
for the self-report to be greater than the MEMS score.
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Validity of self-reported adherencestrength of the association between ad-
herence and HbA1c should also inform
clinicians working with patients with sub-
optimal glycemic control who report being
adherent to their treatment regimen.
Our ﬁndings provide novel informa-
tion on the inﬂuence of characteristics of
self-report measures on the validity of
adherence estimates. Measures asking re-
spondents to report missed doses tended
to over-predict subsequently monitored
MEMS adherence, whereas global quan-
titative self-ratings were more concordant
with subsequent MEMS data. It may be
surprising that less speciﬁc, single-item
global measures resulted in more valid
adherence estimates than more intensive
reviews of missed doses. However, this is
consistent with the literature on the val-
idity of self-reported adherence, which
suggests that patients can provide general
estimates of adherence more accurately
than speciﬁc missed doses (13,30,31). In
contrast to the ﬁndings of Lu et al. (12),
whichshowedthatqualitativeself-ratings
were more accurate than other self-
reports in predicting MEMS adherence,
we found that percentage-based self-
ratings were most strongly associated
with MEMS adherence. Because these
studies differed substantially in the char-
acteristics of their samples, replication of
these results is needed. However, both
studiessuggestthatglobalratingsprovide
morevalidestimatesthanself-reportsthat
rely on a recall of missed doses.
Our ﬁndings also suggest an impor-
tant role for depression severity in the
measurement of self-reported medication
adherence in individuals living with di-
abetes. Analyses revealed signiﬁcant inter-
action effects between depression severity
and several adherence self-reports, the
1-week qualitative and quantitative self-
ratings, and the measure of missed doses
during 1 week, in predicting HbA1c.I n
each case, adherence reports were not as-
sociated with HbA1c levels at higher levels
of depression severity but were signiﬁ-
cantly related at lower levels. The modera-
tion effect was not signiﬁcant for the
SDSCA item regarding adherent days or
the 1-month adherence self-ratings. The
moderating effect of depression is consis-
tent with research demonstrating that
mood can affect memory and recall abili-
ties. Speciﬁcally, studies have consistently
found that clinically depressed individuals
demonstrate a recall bias that favors re-
membering negative stimuli rather than
positive stimuli (32). Therefore, partici-
pants with greater depression severity pos-
sibly remembered themselves as less
adherent than they actually were, whereas
nondepressedparticipantsmoreaccurately
remembered their adherence. We can only
speculate about why the depression effect
was not found for the days-adherent or
1-month self-rating items. It is plausible
that the SDSCA item was less vulnerable
to this effect due to its focus on days of
adherence rather than nonadherence. It is
also plausible that participants were more
likelytoattempttoremembermisseddoses
during the past week when responding to
the 1-week self-ratings but more likely to
rely on a gestalt for their adherence when
providing ratings for 1 month.
We are aware of only one other study
that has examined the role of depression
severity in the concordance between self-
reports for adherence and objectively mea-
sured adherence (26). This study of patients
with hypertension or heart failure found no
signiﬁcant differences in correlations be-
tween self-reported adherence and phar-
macy reﬁll adherence for depressed versus
nondepressed patients. Although not signif-
icant (P = 0.07), this study found that the
correlationbetweenself-reportedadherence
and MEMS adherence was slightly higher
for depressed individuals. However, this
study used two different self-report mea-
sures to screen for depression, treated de-
pression as a categorical variable, and did
not conduct formal tests of moderation.
Thus, results shouldbecompared with cau-
tion. Given the increased prevalence of de-
pressionsymptomsinpatientswithdiabetes
(33)andtheconsistentrelationshipbetween
depression and diabetes treatment non-
adherence (14), the role of depression in
adherence self-reports deserves further in-
vestigation.
Our results should be considered in
the context of our study design. First, our
sample was recruited for a depression
intervention study. Although this limits
the generalizability of our ﬁndings, it
allowed us to examine the effect of rela-
tively severe symptoms of depression.
Second,wewerelimitedinourability
toexaminetheconcordancebetweenself-
reports and MEMS data because these
measures did not cover the same time
frame. On the other hand, this allowed us
to evaluate predictive validity.
Table 3dHierarchical linear regressions assessing interaction effects between self-reported adherence and depression severity in
predicting HbA1c
Variables Adherent days (week) Missed doses (week)
Self-rating (week) Self-rating (month)
Qualitative Quantitative Qualitative Quantitative
Step 1
Insulin 0.954*** 1.064*** 0.929*** 0.920*** 0.955*** 0.948***
Adherence 20.174* 26.152** 20.230** 20.015** 20.260** 20.019***
Step 2
Insulin 0.949*** 1.078*** 0.927*** 0.915*** 0.964*** 0.952***
Adherence 20.172* 26.345** 20.229* 20.015** 20.264** 20.020***
Depression severity 0.001 20.004 0.000 0.001 20.002 20.001
Step 3
Insulin 0.949*** 1.066*** 0.858 0.888*** 0.911*** 0.937
Adherence 20.197* 29.034*** 20.259** 20.018** 20.280** 20.020***
Depression severity 20.001 20.006 0.001 0.002 20.001 0.000
Interaction
a 0.010 0.785** 0.019* 0.001* 0.012 0.000
aTheinteractiontermistheinteractionoftheself-reportedadherencemeasureineachcolumnbydepressionseverity.Threeinteractionsweresigniﬁcantdqualitative,
quantitative, and missed doses 1-week questionsdindicating an interaction effect between those self-report measures and depression severity in predicting HbA1c.
*P , 0.05; **P , 0.01; ***P , 0.001. Note: Data are unstandardized coefﬁcients (and P values) from multiple linear regression models predicting HbA1c.
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Gonzalez and AssociatesThird, MEMS only tracked one
diabetes-related medication, whereas
three self-reports (qualitative, quantita-
tive, and missed doses) asked about all
diabetes-related medications the partici-
pant was taking. In addition, the SDSCA
adherent-days item asked about “diabetes
medication,” though we expect that given
the explicit instructions for the other
items, participants likely answered think-
ing about the same class of medications
used for the other self-report measures.
No self-reports asked speciﬁcally about
adherence to insulin. Furthermore,
only a subset of the original sample, se-
lected for depression severity and subop-
timal glycemic control, was monitored
with MEMS caps. Because this subsample
hadarestrictedrangeofdepressionsever-
ity, we focused our depression modera-
tion analyses on HbA1c only.
Finally, we note that whenever ad-
herencewasmeasured,wewereobtaining
informationonmorethantheingestionof
medication. Research shows that adher-
ence to a placebo is consistently associ-
ated with mortality risk in various patient
populations (34,35). The relationship be-
tween measures of medication adherence
and clinical outcomes likely reﬂects other
behaviors and respondent characteristics
that directly inﬂuence health; this is often
referred to as the “healthy adherer effect.”
G i v e nt h i sc o n t e x t ,w ew e r el e s sc o n -
cerned with speciﬁcally measuring the
link between antihyperglycemic medica-
tion and HbA1c and instead focused on
adherence to the broad class of medica-
tions necessary to manage the risk of di-
abetes complications. Future studies
should build on this work by adapting
these self-report measures to refer to spe-
ciﬁc medications and differentiate be-
tween insulin and oral medications.
The accurate measurement of medi-
cation adherence in diabetes is important
for progress in the development of in-
terventions to improve diabetes self-
managementandforappropriatetreatment
decisions in the delivery of care. Clear ev-
idence demonstrates important negative
health consequences of nonadherence in
patients with diabetes (1). Objective
measures of adherence are often imprac-
tical for various research designs and do
not address the problem of how treat-
ment providers should inquire about
treatment adherence with their patients.
Developing self-report measures of med-
ication adherence with strong validity
would therefore have important beneﬁts
for research and practice. Results of the
current study contribute to our progress
toward this goal and should encourage
further investigation into the best practi-
ces for the assessment of diabetes treat-
ment adherence.
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